The development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure. ⁸⁹Zr-labeled monoclonal antibodies (mAbs), peptides, nanoparticles, proteins, and other compounds are called ⁸⁹Zr-Immuno-PET and are used in cancer tissue imaging. This review provides a general overview of the potential of molecules labeled with ⁸⁹Zr radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies. In light of these studies, radiopharmaceuticals created using nanoparticles have greater potential than those using antibodies.

用于癌组织成像的分子显像剂的开发对于癌症的早期检测具有重要意义。正电子发射断层扫描 (PET) 放射性药物由正电子发射放射性核素和分子结构组成。⁸⁹ Zr 标记的单克隆抗体 (mAb)、肽、纳米颗粒、蛋白质和其他化合物称为⁸⁹ Zr-Immuno-PET，用于癌组织成像。本综述概述了用⁸⁹ Zr 放射性核素标记的分子在临床前和临床研究中的潜力，因其半衰期长而被选中。根据这些研究，使用纳米粒子制造的放射性药物比使用抗体的放射性药物具有更大的潜力。